Research Article
Synthesis and In Vitro Cytotoxic Activity of Chromenopyridones
Table 2
IC50 (μM) of synthesized compounds against various human cancer cell lines.
| Compound number | IC50 ± SE* in μM
| PC-3 (Prostate) | MCF-7 (Breast) | IMR-32 (CNS) | Hela (Cervix) | Hep-G2 (Liver) |
| 3a | 82.4 ± 3.5 | 90.6 ± 2.5 | 80.4 ± 3.5 | >100 | >100 | 3b | 79.2 ± 3.5 | 80.2 ± 3 | >100 | >100 | 90.6 ± 2.5 | 3c | 88.9 ± 2.3 | >100 | 90.4 ± 3.5 | 88.8 ± 1.3 | >100 | 3d | 78.2 ± 2.4 | 86.2 ± 3.5 | 77.4 ± 3.5 | >100 | 83.5 ± 1.2 | 3e | 81.9 ± 2.6 | 83.2 ± 1.5 | 93.2 ± 2.5 | >100 | >100 | 3f | 28.7 ± 3.3 | 39.6 ± 3.5 | 23.9 ± 2.8 | 15.7 ± 3.5 | >100 | 3g | 21.5 ± 2.5 | 23.8 ± 3.2 | 19.2 ± 2.3 | 20.4 ± 1.5 | 44.1 ± 2.1 | 3h | 41.9 ± 3.5 | 15.5 ± 2.3 | >100 | 28.7 ± 1.5 | 85.6 ± 2.2 | 3i | 80.3 ± 1.3 | 54.6 ± 3.8 | 33.7 ± 1.2 | 21.8 ± 3.5 | 54.2 ± 2.6 | 3j | 54.2 ± 2.5 | 33.4 ± 1.2 | 19.2 ± 2.5 | 88.2 ± 3.2 | 38.9 ± 1.1 | 6a | 19.5 ± 2.4 | >100 | 33.5 ± 3.3 | 36.1 ± 2.1 | 44.9 ± 3.2 | 6b | 2.4 ± 3.4 | 10.7 ± 2.5 | 13.2 ± 2.3 | 7.0 ± 3.5 | 16.3 ± 3.5 | 6c | 13.4 ± 1.1 | 11.0 ± 2.3 | 15.6 ± 2.1 | 41.9 ± 3.5 | 23.6 ± 2.5 | 6d | 14.1 ± 2.2 | 14.6 ± 1.5 | 16.3 ± 1.4 | >100 | 41.0 ± 2.3 |
| Paclitaxel | — | 0.2 ± 0.03 | — | — | — | 5-Fluorouracil | — | — | 1.3 ± 0.01 | — | 0.5 ± 0.05 | Mitomycin-C | 1.5 ± 0.02 | — | — | 2.0 ± 0.03 | — |
|
|
*Standard error (±).
|